Display options
Cite
Kheir JM, Guthridge CJ, Johnston JR, et al. Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000247doi: 10.1136/lupus-2017-000247.
Kheir, J. M., Guthridge, C. J., Johnston, J. R., Adams, L. J., Rasmussen, A., Gross, T. F., Munroe, M. E., Bourn, R. L., Sivils, K. L., Guthridge, J. M., Weisman, M. H., Wallace, D. J., Anaya, J. M., Rojas Villarraga, A., Jarvis, J. N., Harley, J. B., & James, J. A. (2018). Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus science & medicine, 5(1), e000247. https://doi.org/10.1136/lupus-2017-000247
Kheir, Joseph M, et al. "Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus." Lupus science & medicine vol. 5,1 (2018): e000247. doi: https://doi.org/10.1136/lupus-2017-000247
Kheir JM, Guthridge CJ, Johnston JR, Adams LJ, Rasmussen A, Gross TF, Munroe ME, Bourn RL, Sivils KL, Guthridge JM, Weisman MH, Wallace DJ, Anaya JM, Rojas Villarraga A, Jarvis JN, Harley JB, James JA. Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med. 2018 Feb 27;5(1):e000247. doi: 10.1136/lupus-2017-000247. eCollection 2018. PMID: 29531773; PMCID: PMC5844376.
Copy Download .nbib Format: NLM
Share it on

Lupus Sci Med. 2018 Feb 27;5(1):e000247. doi: 10.1136/lupus-2017-000247. eCollection 2018.

Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus.

Lupus science & medicine

Joseph M Kheir, Carla J Guthridge, Jonathon R Johnston, Lucas J Adams, Astrid Rasmussen, Timothy F Gross, Melissa E Munroe, Rebecka L Bourn, Kathy L Sivils, Joel M Guthridge, Michael H Weisman, Daniel J Wallace, Juan-Manuel Anaya, Adriana Rojas Villarraga, James N Jarvis, John B Harley, Judith A James

Affiliations

  1. Department of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
  2. Oklahoma State University Health Sciences Center, Tulsa, Oklahoma, USA.
  3. Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  4. Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia.
  5. Artmedica IPS, Bogotá, Colombia.
  6. Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
  7. Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  8. US Department of Veterans Affairs Medical Center, Cincinnati, Ohio, USA.
  9. Department of Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

PMID: 29531773 PMCID: PMC5844376 DOI: 10.1136/lupus-2017-000247

Abstract

OBJECTIVE: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with varied morbidity and mortality. We assessed clinical presentations, autoantibody specificities and therapeutic interventions in Native American (NA) patients with SLE.

METHODS: Patients with SLE meeting 1997 American College of Rheumatology classification criteria (n=3148) were enrolled between 1992 and 2010 in the multiethnic, cross-sectional Lupus Family Registry and Repository. Clinical, demographic and therapeutic information were extracted from medical records using a standardised form and formalised training. Autoantibodies were assessed by indirect immunofluorescence (antinuclear antibodies (ANA) and antidouble-stranded DNA), precipitin (ENA) and ELISA (IgG and IgM anticardiolipins).

RESULTS: NA patients met SLE classification at a younger age (29.89±12.3 years) than European Americans (EA; 32.02±12.87, P=0.0157) and a similar age to African-Americans (AAs) and Hispanics (HIS). More NA patients had concurrent rheumatic diseases or symptoms, such as Raynaud's phenomenon, interstitial lung disease, Sjӧgren's syndrome and systemic sclerosis. Compared with EAs, NAs were more likely to have high-titre ANA (≥1:3240; P<0.0001) and had more SLE-associated autoantibodies. Autoantibodies with unknown specificities were more common in NAs (41%) compared with other racial/ethnic groups in this collection (AA: 24%, P=0.0006; EA: 17%, P<0.0001; HIS: 23%, P=0.0050). Fewer NA patients used hydroxychloroquine (68%) compared with others (AA: 74%, P=0.0308; EA: 79%, P=0.0001, HIS: 77%, P=0.0173); this was influenced by lower hydroxychloroquine use in NA patients from Latin America (32%). NA patients had higher rates of methotrexate use (28%) compared with AA (18%, P=0.0006) and HIS patients (14%, P=0.0003), higher azathioprine use (38%) compared with EA patients (30%, P=0.0105) and higher mycophenolate mofetil use (26%) compared with EA (17%, P=0.0012) and HIS patients (11%, P<0.0001).

CONCLUSIONS: NA patients are diagnosed with SLE earlier in life and present worse concurrent rheumatic disease symptoms than EA patients. NA patients also are more likely to have expanded autoantibody profiles and precipitins of unknown specificities.

Keywords: antinuclear antibodies (ANA); autoantibodies; systemic lupus erythematosus (SLE)

Conflict of interest statement

Competing interests: AR reports personal fees from ThermoFisher for talks regarding diagnosis and classification of Sjögren’s syndrome and the different autoantibody testing platforms.

References

  1. Arthritis Rheum. 1997 Sep;40(9):1725 - PubMed
  2. Rheumatology (Oxford). 2011 Jan;50(1):47-59 - PubMed
  3. Curr Opin Pulm Med. 2000 Sep;6(5):424-9 - PubMed
  4. Clin Rheumatol. 1990 Mar;9(1 Suppl 1):82-94 - PubMed
  5. Arthritis Care Res (Hoboken). 2017 Apr;69(4):467-474 - PubMed
  6. Arthritis Rheum. 1978 May;21(4):473-9 - PubMed
  7. Am J Public Health. 2006 Feb;96(2):363-70 - PubMed
  8. J Rheumatol. 2012 Oct;39(10):1934-41 - PubMed
  9. Curr Diab Rep. 2013 Dec;13(6):814-23 - PubMed
  10. Arthritis Rheumatol. 2014 Sep;66(9):2494-502 - PubMed
  11. J Rheumatol. 2000 Aug;27(8):1884-91 - PubMed
  12. Arthritis Rheum. 2007 May 15;57(4):601-7 - PubMed
  13. Arthritis Rheum. 1992 Jun;35(6):630-40 - PubMed
  14. Medicine (Baltimore). 2004 Jan;83(1):1-17 - PubMed
  15. J Autoimmun. 2016 Nov;74:182-193 - PubMed
  16. Arthritis Rheumatol. 2014 Jul;66(7):1888-99 - PubMed
  17. Q J Med. 1990 Mar;74(275):319-30 - PubMed
  18. Arthritis Rheum. 1982 Nov;25(11):1271-7 - PubMed
  19. Ann N Y Acad Sci. 2008;1136:126-36 - PubMed
  20. Arthritis Care Res (Hoboken). 2017 Aug;69(8):1271-1275 - PubMed
  21. Semin Arthritis Rheum. 1999 Jun;28(6):368-91 - PubMed
  22. J Rheumatol. 1988 Apr;15(4):684-90 - PubMed
  23. Arthritis Rheum. 1999 Mar;42(3):465-74 - PubMed
  24. Arthritis Rheum. 1996 Feb;39(2):283-6 - PubMed
  25. Arthritis Care Res (Hoboken). 2012 Jan;64(1):138-43 - PubMed
  26. Arthritis Rheumatol. 2015 Mar;67(3):752-60 - PubMed
  27. Ann Rheum Dis. 2007 Sep;66(9):1168-72 - PubMed

Publication Types

Grant support